Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b

Hamidi, Mehrdad; Zarrin, Abdolhossein; Foroozesh, Mahshid; Zarei, Najmeh; Mohammadi-Samani, Soliman

doi:10.1016/j.ijpharm.2007.04.001

Cited by 42 publications

(40 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, the results of other studies have shown that turbulence fragility of the carrier erythrocytes increases significantly in comparison with the normal unloaded cells. 1,3,4,7 From the data in Table 4, no significant changes are evident in three hematological indices of nanoparticles-loaded erythrocytes, as expected from the gentle nature of the loading method used. However, these differences are higher in the case of shamencapsulated and drug-loaded cells.…”

Section: In Vitro Characterization Of Carrier Erythrocytesmentioning

confidence: 73%

“…1 Although erythrocytes are the most abundant and readily available cells of the human body, they have gained the highest and the most extensive attention among other cellular carriers for time-controlled or targeted delivery of the drugs and other bioactive agents. [1][2][3][4][5][6][7] In fact, the term "carrier erythrocyte" was first introduced in 1979 to describe the drug-loading capacity of the erythrocytes. 1 There are a series of advantages encouraging the wide spread application of erythrocytes in drug delivery, including, mainly, biocompatibility, complete biodegradability, long life span in circulation, possibility of targeted drug delivery to the reticuloendothelial system (RES) organs, relatively simple and inert intracellular environment, ease of handling, and so on.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Encapsulation of Valproate-Loaded Hydrogel Nanoparticles in Intact Human Erythrocytes: A Novel Nano-cell Composite for Drug Delivery

Hamidi

Rafiei

Azadi

et al. 2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: In Vitro Characterization Of Carrier Erythrocytesmentioning

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Encapsulation of Valproate-Loaded Hydrogel Nanoparticles in Intact Human Erythrocytes: A Novel Nano-cell Composite for Drug Delivery

Hamidi

Rafiei

Azadi

et al. 2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Efficiency of entrapment, the percentage ratio of the loaded amount of PTX to the amount added during the entire loading process. Cell recovery, the percentage ratio of the hematocrit value of the final loaded cells to that of the initial packed cells, measured on equal volumes of two suspensions (Hamidi et al, 2007b).…”

Section: Entrapment Of Ptx Into Erythrocytesmentioning

confidence: 99%

“…In addition, their degradation products are reusable (Pierige`et al, 2008). According to the preferred therapeutic approach, erythrocytes are used either as carriers for the sustained release of the drugs or to target the drugs to specific organs (Hamidi et al, 2007b). The maintenance of the normal oxidant/antioxidant balance in erythrocytes during drug encapsulation may help to produce loaded cells with characteristics similar to those of normal erythrocytes (Alanazi, 2010).…”

Section: Introductionmentioning

confidence: 99%

“…The maintenance of the normal oxidant/antioxidant balance in erythrocytes during drug encapsulation may help to produce loaded cells with characteristics similar to those of normal erythrocytes (Alanazi, 2010). In this case, such drug-loaded cells can be used as slow-release carriers for the entrapped drugs (Hamidi et al, 2007b). In contrast, the modification of loaded erythrocytes results in their accelerated removal and targeting to the reticuloendothelial system (RES) (Alanazi et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel

Harisa

Ibrahim

Alanazi

et al. 2014

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Paclitaxel (PTX) is formulated in a mixture of Cremophor EL and dehydrated alcohol. The intravenous administration of this formula is associated with a risk of infection and hypersensitivity reactions. The presence of Cremophor EL as a pharmaceutical vehicle contributes to these effects. Therefore, in this study, we used human erythrocytes, instead of Cremophor, as a pharmaceutical vehicle. PTX was loaded into erythrocytes using the preswelling method. Analysis of the obtained data indicates that 148.8 lg of PTX was loaded/mL erythrocytes, with an entrapment efficiency of 46.36% and a cell recovery of 75.94%. Furthermore, we observed a significant increase in the mean cell volume values of the erythrocytes, whereas both the mean cell hemoglobin and the mean cell hemoglobin concentration decreased following the loading of PTX. The turbulence fragility index values for unloaded, sham-loaded and PTX-loaded erythrocytes were 3, 2, and 1 h, respectively. Additionally, the erythrocyte glutathione level decreased after PTX loading, whereas lipid peroxidation and protein oxidation increased. The release of PTX from loaded erythrocytes followed first-order kinetics, and about 81% of the loaded drug was released into the plasma after 48 h. The results of the present study revealed that PTX was loaded successfully into human erythrocytes with acceptable loading parameters and with some oxidative modification to the erythrocytes.ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.

show abstract

Engineering of Erythrocytes as Drug Carriers for Therapeutic Applications

Jia,

Shi,

Yan

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

Erythrocytes, also known as red blood cells (RBCs), have garnered considerable attention as potential carriers for drug delivery, owing to their inherent properties such as biocompatibility, biodegradability, and prolonged circulation half‐life. This paper presents a comprehensive overview of the role of erythrocytes in drug delivery, elucidating recent advancements in delivering a diverse array of therapeutic agents, including small molecules, nucleic acids, antibodies, protein enzymes, and nanoparticles. Two primary strategies for encapsulating drugs within erythrocytes are systematically discussed: internal loading and surface loading. Each strategy offers distinct advantages in terms of drug stability and release kinetics. Notably, the utilization of erythrocyte membrane camouflaged nanocarriers holds promise for enhancing the biocompatibility of conventional nanoparticles and facilitating targeted drug delivery. Furthermore, the broad spectrum of biomedical applications of erythrocyte‐based drug delivery systems are examined, ranging from cancer treatment to diabetes management, thrombosis prevention, and immunotherapy. This review provides a comprehensive evaluation of current technologies in erythrocyte‐loaded drug delivery, highlighting the strengths, weaknesses, and future directions for advancing therapeutic interventions in various disease contexts.

show abstract

Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b

Cited by 42 publications

References 26 publications

Encapsulation of Valproate-Loaded Hydrogel Nanoparticles in Intact Human Erythrocytes: A Novel Nano-cell Composite for Drug Delivery

Encapsulation of Valproate-Loaded Hydrogel Nanoparticles in Intact Human Erythrocytes: A Novel Nano-cell Composite for Drug Delivery

Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel

Engineering of Erythrocytes as Drug Carriers for Therapeutic Applications

Contact Info

Product

Resources

About